Track Pacira BioSciences, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Pacira BioSciences, Inc. PCRX · Stock Open Pacira BioSciences, Inc. in new tab

36.46 USD
P/E
39.22
EPS
0.93
P/B
2.04
ROE
5.24
Beta
0.22
Target Price
33.57 USD
Loading chart...
Key Metrics
Earnings dateMarch 4, 2027
P/E39.22
EPS0.93
Book Value17.85
Price to Book2.04
Debt/Equity47.77
% Insiders1.332%
Growth
Revenue Growth-0.02%
Earnings Growth4.83%
Estimates
Forward P/E10.55
Forward EPS3.46
Target Mean Price33.57

DCF valuation

Model fair value for Pacira BioSciences, Inc. (PCRX)
Result
Sign in to run the valuation for PCRX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
7 analysts · consensus None · mean target 33.57 USD (low 25.00, high 36.50) · as of 12 Nov 2026
Low 25.00
Mean 33.57
High 36.50
Price 36.46
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Pacira BioSciences, Inc. Logo Pacira BioSciences, Inc. Analysis (PCRX)

United States Health Care Official Website Stock

Is Pacira BioSciences, Inc. a good investment? Pacira BioSciences, Inc. (PCRX) is currently trading at 36.46 USD. Market analysts have a consensus price target of 33.57 USD. This suggests the asset is currently trading above analyst expectations.

In terms of valuation, the stock trades at a P/E ratio of 39.22. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Pacira BioSciences, Inc. is expected to release its next earnings report on March 4, 2027. The market consensus estimate for Forward EPS is 3.46.

Investor FAQ

Does Pacira BioSciences, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Pacira BioSciences, Inc.?

Pacira BioSciences, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 4, 2027. The company currently has a trailing EPS of 0.93.

Company Profile

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.

Exchange Ticker
NMS (United States) PCRX
FRA (Germany) 82P.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion